Why It Matters
Asia is the epicentre of a looming eye‑health crisis: by 2050, nearly half the world's population could be myopic, with Singapore already reporting rates above 80% in teens and young adults. High myopia dramatically increases lifetime risks of retinal detachment, glaucoma and other sight‑threatening complications.
Maxight's patented D.I.T. display projects study materials onto a virtual 6‑metre "outdoor" plane, reducing accommodative stress and slowing axial‑length growth in children. Peer‑reviewed trials of the platform's low‑level red‑light photobiomodulation report significant retardation of myopia progression.
Flagship Product Line
| Product | Key Benefit |
|---|---|
| Maxight Pro | Immersive desktop optical engine with AI study companion |
| Maxight Kid | Portable, family‑friendly variant enabling multi‑device "Safe Eye Mode" |
| Maxight Reader | Entry‑level reading & writing device that keeps books and smart devices at a myopia‑safe distance |
Event Highlights & Expert Voices
- Academic keynote: "Today's Myopia Crisis — Trends & Breakthrough Interventions" by Mr Ken Tong, Founder & CEO, eyesight.sg, former President of the Singapore Optometric Association.
- Round‑table: Moderated by Dr Ivan Leung, Senior Lecturer, Singapore Polytechnic School of Chemical & Life Sciences, with panelists Dr Rupesh Agrawal, Head of Research, NHG Eye Institute, and Dr Ivy Zhang, Founder & CEO, Maxight.
- Closing remarks: Dr Li Lian Foo, Clinical Director, Myopia Service, Singapore National Eye Centre, who called the launch "a milestone in our mission to fight rising myopia."
These leaders were joined by dozens of community ophthalmologists, paediatric optometrists, school health‑service officers, healthcare investors and med‑tech engineers, underscoring the multidisciplinary momentum behind evidence‑based myopia control.
Partnering for Impact
Maxight is finalising collaborations with the Singapore Polytechnic Optometry Centre (SPOC) and the Singapore National Eye Centre (SNEC) Myopia Centre to embed D.I.T. modules into school screening programmes and accelerate longitudinal research.
About Maxight
Founded in 2023, MAXIGHT TECHNOLOGY PTE LTD is a deep‑tech company dedicated to "Empowering Clearer Vision." Headquartered in Singapore, with R&D hubs in Beijing and manufacturing facilities in Shenzhen, Maxight pioneers immersive optics, AI‑driven engagement and clinically validated photobiomodulation for parents, schools and paediatric clinics across Asia.
Terminology
D.I.T. – Distant Imaging Therapy
A patented optical‑display technique that projects digital content onto a virtual 6 m plane, reducing accommodative stress and slowing axial elongation in paediatric eyes.
D.I.L.T. – Digital Long‑wave Light Therapy
A non‑laser, low‑intensity red‑light (650–800 nm) photobiomodulation protocol delivered through Maxight's display system to induce hyperopic shift, thicken the choroid and bolster ocular health.
